MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/mpg.0000000000001679

Медицинская библиотека · Journal of pediatric gastroenterology and nutrition · 2018

Real-life Anti-tumor Necrosis Factor Experience in More Than 500 Patients: High Co-immunosuppression Rates But Low Rates of Quantifying Treatment Response.

Merrick Victoria M, Mortier Kajal, Williams Linda J, Muhammed Rafeeq, Auth Marcus K H, Elawad Mamoun, Fell John M E, Beattie R Mark, Loganathan Sabarinathan, Torrente Franco, Morris Mary-Anne, Charlton Charles, Croft Nick M, Rodrigues Astor, Furman Mark, Vadamalayan Babu, Jenkins Huw, Zamvar Veena, Mitton Sally G, Chong Sonny, Cosgrove Mike, Akobeng Anthony, Wilson David C, Russell Richard K

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

The aim of this study was to measure the effectiveness, safety, and use of anti-tumor necrosis Factor (TNF) therapy in pediatric inflammatory bowel disease in the United Kingdom (UK).

METHODS

Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment +/or the Paediatric Crohn Disease Activity Index.

RESULTS

A total of 37 centers participated (23/25 specialist pediatric inflammatory bowel disease sites). A total of 524 patients were included: 429 with Crohn disease (CD), 76 with ulcerative colitis (UC), and 19 with IBD unclassified (IBDU). Eighty-seven percent (488/562) of anti-TNF was infliximab; commonest indication was active luminal CD 77% (330/429) or chronic refractory UC/IBDU 56% (53/95); 79% (445/562) had concomitant co-immunosuppression. In CD (267/429 male), median time from diagnosis to treatment was 1.42 years (interquartile range 0.63-2.97). Disease (at initiation) was moderate or severe in 91% (156/171) by Physician Global Assessment compared to 41% (88/217) by Paediatric Crohn Disease Activity Index (Kappa (κ) 0.28 = only "fair agreement"; P < 0.001.Where documented, 77% (53/69) of patients with CD responded to induction; and 65% (46/71) entered remission. A total of 2287 infusions and 301.96 years of patient' follow-up (n = 385) are represented; adverse events affected 3% (49/1587) infliximab and 2% (2/98) adalimumab infusions (no deaths or malignancies). Peri-anal abscess drainage was less common after anti-TNF initiation (CD), that is 26% (27/102) before, 7% (3/42) after (P = 0.01); however, pre and post anti-TNF data collection was not over equal time periods.

CONCLUSIONS

Anti-TNFs are effective treatments, usually given with thiopurine co-immunosuppression. This study highlights deficiencies in formal documentation of effect and disparity between disease severity scoring tools, which need to be addressed to improve ongoing patient care.

Для цитирования: Merrick Victoria M, Mortier Kajal, Williams Linda J, Muhammed Rafeeq, Auth Marcus K H, Elawad Mamoun, Fell John M E, Beattie R Mark, Loganathan Sabarinathan, Torrente Franco, Morris Mary-Anne, Charlton Charles, Croft Nick M, Rodrigues Astor, Furman Mark, Vadamalayan Babu, Jenkins Huw, Zamvar Veena, Mitton Sally G, Chong Sonny, Cosgrove Mike, Akobeng Anthony, Wilson David C, Russell Richard K. Real-life Anti-tumor Necrosis Factor Experience in More Than 500 Patients: High Co-immunosuppression Rates But Low Rates of Quantifying Treatment Response.. Journal of pediatric gastroenterology and nutrition. 2018. DOI: 10.1097/mpg.0000000000001679.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.